
AbstractFriedreich ataxia (FRDA) is a metabolic disease with two faces. Loss of iron–sulfur cluster biogenesis disables oxidative phosphorylation, the Krebs cycle and the oxidation of fatty acids and ketone bodies, forcing tissues onto glycolysis and stranding lipid in droplets and as ceramide. The second aspect is on the supply side. A frataxin-deficient liver and adipose tissue deliver inadequate lipoprotein, fatty acid and ketone cargo to the heart, skeletal muscle and nervous system, the organs that depend most on imported fuel. Together, these lesions produce a cardiomyopathy that behaves like an engine out of fuel, a mixed diabetes of insulin deficiency and insulin resistance, low lean and bone mass and a redox-collapsed, ferroptosis-prone state. This review traces that logic from the cell to the organ to the whole body. The same map defines a compact panel of blood-based biomarkers, anchored on frataxin protein itself and extended by chain-resolved ceramides and by the succinate : fumarate, BHB : acetoacetate, NAD+ : NADH and GSH : GSSG ratios. It also nominates targets that do not require restoration of frataxin, including NRF2 activation, ferroptosis inhibition, NAD+ and sirtuin repletion, PPARgamma agonism, anaplerosis and ketone-based therapy. Reframing FRDA as a disorder of fuel logistics, rather than of fuel combustion alone, explains why a globally reduced protein produces a selective yet multisystem disease.
AbstractCells must continuously distinguish cellular-derived RNA from pathogenic RNA to mount effective antiviral responses while avoiding harmful autoinflammation. Cytoplasmic RNA-sensing receptors, including RIG-I-like receptors, PKR, OAS-RNase L and ZBP1, detect RNA primarily through molecular features such as structure (double- versus single-stranded), modification state and subcellular localization rather than sequence. While these are characteristics of viral nucleic acids, mammalian genomes generate abundant self-derived double-stranded RNA (dsRNA), including from transposable elements, antisense transcription and RNA processing intermediates, which exist in the cytoplasm. This review describes our current understanding of how cells achieve self-tolerance through the active regulation of endogenous RNA. These mechanisms comprise epigenetic silencing of repetitive elements, RNA modifications (such as A-to-I editing and m6A), precise splicing, regulated nuclear export and decay, circRNA buffering, protein shielding and dedicated RNA degradation pathways. Insights from rare inherited monogenic interferonopathies and murine models illustrate how perturbations in these pathways lead to inappropriate activation of cytoplasmic RNA sensors and inflammatory disease when cellular dsRNA is mistakenly recognized as non-self. We highlight how dysregulated dsRNA homeostasis contributes to common autoimmune and neuroinflammatory disorders. Understanding how cells regulate endogenous dsRNA is crucial for defining disease mechanisms and developing new therapeutic strategies.
AbstractRare variants in NEK1, encoding a serine/threonine kinase, are among the most consistently implicated genetic contributors to amyotrophic lateral sclerosis (ALS), reported in approximately 2–3% of cases. Yet, while recent studies have characterized the cell biological consequences of NEK1 loss-of-function, the biochemical effects of ALS-associated missense variants on kinase activity have not been directly investigated. This distinction is mechanistically important, because missense alleles encode mutant proteins rather than simply reducing protein dosage. Here, we provide the most comprehensive cell-based phosphoproteomic map of NEK1 phosphorylation to date, identifying 10 recurrent phosphorylation sites across independent expression and acquisition conditions. We experimentally assign pSer14, pThr156 and pSer418 as NEK1 autophosphorylation sites using kinase-dead controls, targeted extracted ion chromatogram analysis, phosphosite mutagenesis and phosphospecific antibodies. Leveraging activation-loop pThr156 as a read-out of NEK1 activity, we assessed nine ALS-associated missense variants spanning the major functional regions of the protein. Among catalytic-domain variants, R261C produced the most robust reduction in pThr156 autophosphorylation, R232C produced a smaller reduction, and R232H increased pThr156; the basic-region variant, A313T, also showed a smaller reduction. Structural modelling provides a mechanistic framework for understanding these variant-specific effects. Our study establishes the first activity-based framework for functional classification of NEK1 missense variants, and provides direct evidence that ALS-associated missense variants can alter NEK1 autophosphorylation through a mechanism distinct from simple haploinsufficiency. The phosphospecific antibodies, isogenic cell lines and curated phosphoproteomic datasets generated here provide a community resource for future studies of NEK1 regulation, variant interpretation and therapeutic target validation.
AbstractHuman fertility is regulated by a complex, integrated network of biological systems that collectively determine reproductive competence in males and females. Conventional fertility assessment relies on established clinical biomarkers, including reproductive hormone profiles, gamete-based functional assessments and imaging indicators of gonadal structure and function. While clinically informative, these measures capture only partial views of molecular and cellular processes underlying gametogenesis and reproductive capacity. Recent advances in reproductive medicine have expanded the biomarker landscape through genetic and epigenetic profiling, enabling identification of pathogenic variants, chromosomal abnormalities and regulatory modifications associated with infertility syndromes. In parallel, multi-omics approaches are increasingly being used to characterize molecular networks governing gamete development, meiotic integrity, DNA repair and cellular differentiation. This review presents a comprehensive synthesis of fertility biomarkers, spanning endocrine, genetic, epigenetic, structural, metabolic and inflammatory systems. Current evidence is examined on endocrine and reproductive hormone biomarkers, followed by an investigation of genetic and epigenetic markers of reproductive dysfunction, as well as structural and imaging-based biomarkers and inflammatory and metabolic indicators. Finally, emerging biomarker platforms are highlighted as key advances towards precision reproductive medicine. Collectively, these developments support a shift towards a more comprehensive, biomarker-driven framework for the evaluation and management of infertility.
Abstract Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone that governs the folding, stabilization and activity of a wide range of client proteins, many of which are critical regulators of immune cell signalling and inflammatory responses. Recent research has underscored the role of Hsp90 in orchestrating both innate and adaptive immune functions, particularly in the context of autoimmune diseases. In autoimmune diseases, dysregulated immune pathways often involve Hsp90-dependent client proteins, including key kinases and transcription factors. By modulating the activation, differentiation and survival of immune cells Hsp90 emerges as a central node in autoimmune pathogenesis. Importantly, the pharmacological inhibition of Hsp90 has shown promise in preclinical models of autoimmunity, where it attenuates pro-inflammatory pathways. In this review, we examine the immunoregulatory functions of Hsp90 with a focus on autoimmune disorders, highlighting its role in disease-driving pathways, such as Nuclear Factor Kappa B (NF-κB), Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) and Mitogen-Activated Protein Kinase (MAPK). We also discuss the current landscape of Hsp90 inhibitors, their mechanism of action, and emerging data on their efficacy in autoimmune disease models. Understanding how Hsp90 shapes immune cell behaviour and inflammation provides a compelling framework for its development as a novel therapeutic target in chronic autoimmune conditions.